Bluejay Diagnostics (NASDAQ:BJDX) Stock Rating Upgraded by Wall Street Zen

Bluejay Diagnostics (NASDAQ:BJDX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

BJDX opened at $1.05 on Friday. The stock has a market capitalization of $1.08 million, a price-to-earnings ratio of -0.09 and a beta of 0.89. The business has a 50-day moving average of $2.08 and a two-hundred day moving average of $2.20. Bluejay Diagnostics has a 12 month low of $0.83 and a 12 month high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares in the company, valued at approximately $128,877. The trade was a 27.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by hedge funds and other institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.